In the validation cohort, there were no significant changes in IGF-1 between non-obese controls (115.75 ± 15.69 ng/ml), obese controls (105.83 ± 15.62 ng/ml), NAFL (122.30 ± 6.05 ng/ml), and NASH (103.50 ± 3.98 ng/ml), although an inverse correlation with BMI was observed (n = 199; Spearman r = −0.1647; 95% CI, 0.30-−0.02; p < 0.05) (Figures 4A,B). The gene discussed is IGF1; the disease is metabolic dysfunction-associated steatohepatitis.